Pancreatic cancer stromal biology and therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
DeSantis, 2014, Cancer treatment and survivorship statistics, 2014, CA Cancer J Clin, 64, 252, 10.3322/caac.21235
Bednar, 2014, Recent advances in pancreatic surgery, Curr Opin Gastroenterol, 30, 518, 10.1097/MOG.0000000000000096
Karachristos, 2014, Surgical management of pancreatic neoplasms: what's new?, Curr Gastroenterol Rep, 16, 397, 10.1007/s11894-014-0397-x
Bliss, 2014, Outcomes in operative management of pancreatic cancer, J Surg Oncol, 110, 592, 10.1002/jso.23744
McCarroll, 2014, Role of pancreatic stellate cells in chemoresistance in pancreatic cancer, Front Physiol, 5, 141, 10.3389/fphys.2014.00141
Xie, 2006, Transcriptional anti-angiogenesis therapy of human pancreatic cancer, Cytokine Growth Factor Rev, 17, 147, 10.1016/j.cytogfr.2006.01.002
Huang, 2012, Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis, Cytokine Growth Factor Rev, 23, 25, 10.1016/j.cytogfr.2012.01.003
Quan, 2013, The roles of FOXM1 in pancreatic stem cells and carcinogenesis, Mol Cancer, 12, 159, 10.1186/1476-4598-12-159
Haddad, 2011, Hereditary pancreatic and hepatobiliary cancers, Int J Surg Oncol, 2011, 154673
Brentnall, 2005, Management strategies for patients with hereditary pancreatic cancer, Curr Treat Options Oncol, 6, 437, 10.1007/s11864-005-0046-6
Kimura, 1998, Problems in the diagnosis and treatment of a so-called mucin-producing tumor of the pancreas, Pancreas, 16, 363, 10.1097/00006676-199804000-00025
Neesse, 2011, Stromal biology and therapy in pancreatic cancer, Gut, 60, 861, 10.1136/gut.2010.226092
Cowan, 2014, Genetic progression of pancreatic cancer, Cancer J, 20, 80, 10.1097/PPO.0000000000000011
Rustgi, 2014, Familial pancreatic cancer: genetic advances, Genes Dev, 28, 1, 10.1101/gad.228452.113
Wood, 2012, Pathology and molecular genetics of pancreatic neoplasms, Cancer J, 18, 492, 10.1097/PPO.0b013e31827459b6
Kindler, 2011, Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study, Lancet Oncol, 12, 256, 10.1016/S1470-2045(11)70004-3
Stromnes, 2014, Stromal reengineering to treat pancreas cancer, Carcinogenesis, 35, 1451, 10.1093/carcin/bgu115
Neesse, 2013, Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma, Onco Targets Ther, 7, 33, 10.2147/OTT.S38111
McCleary-Wheeler, 2012, Aberrant signaling pathways in pancreatic cancer: a two compartment view, Mol Carcinog, 51, 25, 10.1002/mc.20827
Maitra, 2005, Precursors to invasive pancreatic cancer, Adv Anat Pathol, 12, 81, 10.1097/01.pap.0000155055.14238.25
Heinmoller, 2000, Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma, Am J Pathol, 157, 83, 10.1016/S0002-9440(10)64520-8
Yamano, 2000, Genetic progression and divergence in pancreatic carcinoma, Am J Pathol, 156, 2123, 10.1016/S0002-9440(10)65083-3
Klimstra, 1994, K-ras mutations in pancreatic ductal proliferative lesions, Am J Pathol, 145, 1547
Rozenblum, 1997, Tumor-suppressive pathways in pancreatic carcinoma, Cancer Res, 57, 1731
Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368
Kim, 2014, Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines, Mol Cells, 37, 888, 10.14348/molcells.2014.0207
Pilarsky, 2014, Genomics of pancreatic ductal adenocarcinoma, Hepatobiliary Pancreat Dis Int, 13, 381, 10.1016/S1499-3872(14)60281-2
Caba, 2014, Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers, Dig Dis Sci, 59, 2714, 10.1007/s10620-014-3291-3
Lili, 2014, Evidence for the importance of personalized molecular profiling in pancreatic cancer, Pancreas, 43, 198, 10.1097/MPA.0000000000000020
Shain, 2013, Integrative genomic and functional profiling of the pancreatic cancer genome, BMC Genomics, 14, 624, 10.1186/1471-2164-14-624
Zhang, 2013, Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer, Clin Cancer Res, 19, 4983, 10.1158/1078-0432.CCR-13-0209
Chen, 2013, Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of complement C3 and alpha-2-HS-glycoprotein, Pancreatology, 13, 290, 10.1016/j.pan.2013.03.010
Bond, 2013, Identification of chemosensitive pancreatic cancer with gene profiling, Biomark Med, 7, 200
Brandi, 2013, Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists, Electrophoresis, 34, 1359, 10.1002/elps.201200402
Kong, 2012, Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications, Cytokine Growth Factor Rev, 23, 343, 10.1016/j.cytogfr.2012.06.006
Kozuka, 1979, Relation of pancreatic duct hyperplasia to carcinoma, Cancer, 43, 1418, 10.1002/1097-0142(197904)43:4<1418::AID-CNCR2820430431>3.0.CO;2-O
Petersen, 1992, Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells, Proc Natl Acad Sci USA, 89, 9064, 10.1073/pnas.89.19.9064
Froeling, 2009, Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells, Am J Pathol, 175, 636, 10.2353/ajpath.2009.090131
Cousin, 2009, Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo, PLoS One, 4, e6278, 10.1371/journal.pone.0006278
Issa, 2014, Treatment options for chronic pancreatitis, Nat Rev Gastroenterol Hepatol, 11, 556, 10.1038/nrgastro.2014.74
Pinho, 2014, Chronic pancreatitis: a path to pancreatic cancer, Cancer Lett, 345, 203, 10.1016/j.canlet.2013.08.015
Kloppel, 2007, Chronic pancreatitis, pseudotumors and other tumor-like lesions, Mod Pathol, 20, 113, 10.1038/modpathol.3800690
Whitcomb, 2004, Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer, Am J Physiol Gastrointest Liver Physiol, 287, G315, 10.1152/ajpgi.00115.2004
Malka, 2002, Risk of pancreatic adenocarcinoma in chronic pancreatitis, Gut, 51, 849, 10.1136/gut.51.6.849
Whitcomb, 2002, Pancreatitis as a risk for pancreatic cancer, Gastroenterol Clin North Am, 31, 663, 10.1016/S0889-8553(02)00004-3
Rhim, 2012, EMT and dissemination precede pancreatic tumor formation, Cell, 148, 349, 10.1016/j.cell.2011.11.025
Whitcomb, 1996, Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene, Nat Genet, 14, 141, 10.1038/ng1096-141
Hwang, 2008, Cancer-associated stromal fibroblasts promote pancreatic tumor progression, Cancer Res, 68, 918, 10.1158/0008-5472.CAN-07-5714
Xu, 2010, Role of pancreatic stellate cells in pancreatic cancer metastasis, Am J Pathol, 177, 2585, 10.2353/ajpath.2010.090899
Li, 2015, Activation of Vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemesss, Clin Cancer Res, 21, 844, 10.1158/1078-0432.CCR-14-2437
Özdemir, 2014, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell, 25, 719, 10.1016/j.ccr.2014.04.005
Studeny, 2004, Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents, J Natl Cancer Inst, 96, 1593, 10.1093/jnci/djh299
Studeny, 2002, Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors, Cancer Res, 62, 3603
Kallifatidis, 2008, Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer, Cancer Gene Ther, 15, 231, 10.1038/sj.cgt.7701097
Ghaedi, 2011, Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors, J Gene Med, 13, 171, 10.1002/jgm.1552
Ronnov-Jessen, 1995, The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells, J Clin Invest, 95, 859, 10.1172/JCI117736
Tomasek, 2002, Myofibroblasts and mechano-regulation of connective tissue remodelling, Nat Rev Mol Cell Biol, 3, 349, 10.1038/nrm809
Udagawa, 2006, Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells, FASEB J, 20, 95, 10.1096/fj.04-3669com
Ogawa, 2006, Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications, Blood, 108, 2893, 10.1182/blood-2006-04-016600
Spaeth, 2009, Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression, PLoS One, 4, e4992, 10.1371/journal.pone.0004992
Nakamizo, 2005, Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas, Cancer Res, 65, 3307, 10.1158/0008-5472.CAN-04-1874
Hung, 2005, Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging, Clin Cancer Res, 11, 7749, 10.1158/1078-0432.CCR-05-0876
Karnoub, 2007, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, 449, 557, 10.1038/nature06188
Faouzi, 1999, Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study, J Hepatol, 30, 275, 10.1016/S0168-8278(99)80074-9
Powell, 1999, Myofibroblasts. I. Paracrine cells important in health and disease, Am J Physiol, 277, C1, 10.1152/ajpcell.1999.277.1.C1
Phan, 2002, The myofibroblast in pulmonary fibrosis, Chest, 122, 286S, 10.1378/chest.122.6_suppl.286S
Desmouliere, 2003, Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis, Lab Invest, 83, 1689, 10.1097/01.LAB.0000101911.53973.90
Petersen, 2003, Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma, Am J Pathol, 162, 391, 10.1016/S0002-9440(10)63834-5
Lee, 1999, Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells, Invest Ophthalmol Vis Sci, 40, 2025
Oldfield, 2001, Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE), J Clin Invest, 108, 1853, 10.1172/JCI11951
Li, 2004, Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway, Am J Pathol, 164, 1389, 10.1016/S0002-9440(10)63225-7
Nightingale, 2004, Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation, J Am Soc Nephrol, 15, 21, 10.1097/01.ASN.0000102479.92582.43
Willis, 2005, Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis, Am J Pathol, 166, 1321, 10.1016/S0002-9440(10)62351-6
Kim, 2006, Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix, Proc Natl Acad Sci USA, 103, 13180, 10.1073/pnas.0605669103
Selman, 2006, Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers, Proc Am Thorac Soc, 3, 364, 10.1513/pats.200601-003TK
Gudjonsson, 2005, Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia, J Mammary Gland Biol Neoplasia, 10, 261, 10.1007/s10911-005-9586-4
Moinfar, 2000, Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis, Cancer Res, 60, 2562
Folkman, 2002, Role of angiogenesis in tumor growth and metastasis, Semin Oncol, 29, 15, 10.1053/sonc.2002.37263
Folkman, 2003, Fundamental concepts of the angiogenic process, Curr Mol Med, 3, 643, 10.2174/1566524033479465
Folkman, 1990, What is the evidence that tumors are angiogenesis dependent?, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4
Wang, 2010, Glioblastoma stem-like cells give rise to tumour endothelium, Nature, 468, 829, 10.1038/nature09624
Ricci-Vitiani, 2010, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature, 468, 824, 10.1038/nature09557
Vogelmann, 2001, Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model, Am J Physiol Gastrointest Liver Physiol, 280, G164, 10.1152/ajpgi.2001.280.1.G164
Lohr, 2001, Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma, Cancer Res, 61, 550
Bardeesy, 2006, Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer, Genes Dev, 20, 3130, 10.1101/gad.1478706
Duda, 2003, Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells, Oncogene, 22, 6857, 10.1038/sj.onc.1206751
Schwarte-Waldhoff, 2000, Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis, Proc Natl Acad Sci USA, 97, 9624, 10.1073/pnas.97.17.9624
Aoki, 2007, Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines, Am J Physiol Cell Physiol, 292, C259, 10.1152/ajpcell.00030.2006
Levy, 2005, Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses, Mol Cell Biol, 25, 8108, 10.1128/MCB.25.18.8108-8125.2005
Melisi, 2008, LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis, Mol Cancer Ther, 7, 829, 10.1158/1535-7163.MCT-07-0337
Medicherla, 2007, Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment, Anticancer Res, 27, 4149
Schlingensiepen, 2006, Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009, Cytokine Growth Factor Rev, 17, 129, 10.1016/j.cytogfr.2005.09.002
Blaine, 2009, Epidermal growth factor receptor regulates pancreatic fibrosis, Am J Physiol Gastrointest Liver Physiol, 297, G434, 10.1152/ajpgi.00152.2009
Dong, 2004, VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis, EMBO J, 23, 2800, 10.1038/sj.emboj.7600289
Yu, 2003, Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53, J Biol Chem, 278, 49582, 10.1074/jbc.M309986200
Xie, 2003, Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers, Cancer Cell, 4, 245, 10.1016/S1535-6108(03)00246-0
Teglund, 2010, Hedgehog beyond medulloblastoma and basal cell carcinoma, Biochim Biophys Acta, 1805, 181
Thayer, 2003, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis, Nature, 425, 851, 10.1038/nature02009
Berman, 2003, Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours, Nature, 425, 846, 10.1038/nature01972
Feldmann, 2007, Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers, Cancer Res, 67, 2187, 10.1158/0008-5472.CAN-06-3281
Yauch, 2008, A paracrine requirement for hedgehog signalling in cancer, Nature, 455, 406, 10.1038/nature07275
Tian, 2009, Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis, Proc Natl Acad Sci USA, 106, 4254, 10.1073/pnas.0813203106
Bailey, 2008, Sonic hedgehog promotes desmoplasia in pancreatic cancer, Clin Cancer Res, 14, 5995, 10.1158/1078-0432.CCR-08-0291
Olive, 2009, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324, 1457, 10.1126/science.1171362
Hu, 2007, Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells, Acta Pharmacol Sin, 28, 1224, 10.1111/j.1745-7254.2007.00620.x
Kelsen, 1997, Pain as a predictor of outcome in patients with operable pancreatic carcinoma, Surgery, 122, 53, 10.1016/S0039-6060(97)90264-6
Pelaez-Luna, 2007, Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis, Am J Gastroenterol, 102, 2157, 10.1111/j.1572-0241.2007.01480.x
Szafranska, 2008, Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues, Clin Chem, 54, 1716, 10.1373/clinchem.2008.109603
Li, 2010, Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels, Cancer Res, 70, 5226, 10.1158/0008-5472.CAN-09-4227
Pilarsky, 2008, Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling, J Cell Mol Med, 12, 2823, 10.1111/j.1582-4934.2008.00289.x
Binkley, 2004, The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma, Pancreas, 29, 254, 10.1097/00006676-200411000-00003
Allinen, 2004, Molecular characterization of the tumor microenvironment in breast cancer, Cancer Cell, 6, 17, 10.1016/j.ccr.2004.06.010
Sultana, 2007, Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy, Br J Cancer, 96, 1183, 10.1038/sj.bjc.6603719
Huguet, 2007, Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies, J Clin Oncol, 25, 326, 10.1200/JCO.2006.07.5663
Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403
Ueda, 2004, The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma, Pancreas, 29, e1, 10.1097/00006676-200407000-00061
Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525
Furukawa, 1995, Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis, Am J Pathol, 147, 889
Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691
Kindler, 2010, Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303), J Clin Oncol, 28, 3617, 10.1200/JCO.2010.28.1386
Van Cutsem, 2009, Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer, J Clin Oncol, 27, 2231, 10.1200/JCO.2008.20.0238
Bramhall, 1997, Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma, J Pathol, 182, 347, 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J
Bramhall, 2001, Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial, J Clin Oncol, 19, 3447, 10.1200/JCO.2001.19.15.3447
Bramhall, 2002, A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer, Br J Cancer, 87, 161, 10.1038/sj.bjc.6600446
Moore, 2003, Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 21, 3296, 10.1200/JCO.2003.02.098
Infante, 2007, Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma, J Clin Oncol, 25, 319, 10.1200/JCO.2006.07.8824
Nyman, 2005, Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies, J Clin Oncol, 23, 7785, 10.1200/JCO.2004.00.6148
Von Hoff, 2011, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial, J Clin Oncol, 29, 4548, 10.1200/JCO.2011.36.5742
Borazanci, 2014, Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer, Expert Rev Gastroenterol Hepatol, 8, 739, 10.1586/17474124.2014.925799
Porter, 2014, Nab-paclitaxel plus gemcitabine regimen for pancreatic Cancer, Hosp Pharm, 49, 18, 10.1310/hpj4901-18
Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369